Literature DB >> 34436960

SARS-CoV-2 among the Potential Viral Triggers for Vogt-Konayagi-Harada Disease: First Case Report and Literature Review.

Ana Santamaria1, Julian Chang1, Christian Savarain2.   

Abstract

OBJECTIVE: To describe a case of Vogt-Koyanagi-Harada (VKH) disease associated with the novel coronavirus disease 2019 (COVID-19).
MATERIALS AND METHODS: A retrospective review of patient records was carried out to obtain data for a case report. A literature review was conducted of cases of uveitis associated with COVID-19 reported to date. CASE DESCRIPTION: A 32-year-old Hispanic female presented with bilateral granulomatous panuveitis consisting of VKH disease 2 weeks after a clinical course of COVID-19. Both eyes presented with anterior uveitis and edematous hyperemic papilla with flame-shaped peripapillary hemorrhages, macula-off serous retinal detachments with subretinal fluid, and vitritis. A complete systemic work-up was performed to exclude infectious or inflammatory etiologies. Ocular inflammatory signs and systemic symptoms improved with corticosteroid and immunomodulatory therapy.
CONCLUSION: SARS-CoV-2 can be a potential immunological trigger for VKH disease. Patients presenting with panuveitis and a history of a previous flu-like illness should raise clinical suspicion of the presence of SARS-CoV-2 in the context of the ongoing global pandemic.

Entities:  

Keywords:  SARS-CoV-2; Vogt–Koyanagi–Harada; optic neuritis; uveitis

Year:  2021        PMID: 34436960     DOI: 10.1080/09273948.2021.1966052

Source DB:  PubMed          Journal:  Ocul Immunol Inflamm        ISSN: 0927-3948            Impact factor:   3.070


  2 in total

1.  Probable Vogt-Koyanagi-Harada Disease after COVID-19 Vaccination: Case Report and Literature Review.

Authors:  Xinyi Ding; Qing Chang
Journal:  Vaccines (Basel)       Date:  2022-05-16

2.  Vogt Koyanagi Harada disease following a recent COVID-19 infection.

Authors:  Eliza Anthony; Archana Rajamani; Prabu Baskaran; Anand Rajendran
Journal:  Indian J Ophthalmol       Date:  2022-02       Impact factor: 2.969

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.